logo
ProjectEnded

Precision Therapies in Lung Squamous Cell Carcinoma

The status, timeline and source of this project. A free account opens every field.

Source: EU Funding & Tenders Portal

Lung squamous cell carcinoma (LSCC) represents one third of lung tumours; 550,000 cases are diagnosed annually worldwide (20% occur in Europe). Treatment options for this cancer type are still scarce. Identification of LSCC genetic drivers is thus an essential unmet need for developing novel therapies for this disease. In a stepwise multidisciplinary approach, we will determine if TNIK (Traf-2 and

Status
Closed
Sector
Education
Location
United Kingdom
Updated
22 Jul 2026
Source
EU Funding & Tenders Portal

ConstructChat

Ask ConstructChat about Precision Therapies in Lung Squamous Cell Carcinoma

Pick a question to edit it, or write your own.

First answer free · no account

I am a

Project Information FAQ

Project Information

3 Q
The project “Precision Therapies in Lung Squamous Cell Carcinoma” is an infrastructure initiative in the Education sector, located in United Kingdom. Taiyo aggregates data on it from EU Funding & Tenders Portal.

Participants

Not available for this record.

Status

Original status

ended

Taiyo status

Closed

Taiyo last update

2026-07-22

Contact

Not available for this record.

Description

Description

Lung squamous cell carcinoma (LSCC) represents one third of lung tumours; 550,000 cases are diagnosed annually worldwide (20% occur in Europe). Treatment options for this cancer type are still scarce. Identification of LSCC genetic drivers is thus an essential unmet need for developing novel therapies for this disease. In a stepwise multidisciplinary approach, we will determine if TNIK (Traf-2 and Nck-interacting kinase), a gene amplified in almost 40% of LSCC cases, constitutes a therapeutic target for the treatment of LSCC patients. Our preliminary data show that TNIK is overexpressed in LSCC cells, in which it has a pro-oncogenic role. Using proteomics approaches and functional assays, we will define the molecular mechanisms and critical signalling pathways that TNIK modulates to promote LSCC progression. In xenograft models we will confirm the contribution of TNIK to the studied phenotypes in vivo. We will analyse TNIK levels and activity (after identification of substrates) in patient samples, and will aim to validate TNIK as a target for therapeutic intervention using small molecule TNIK inhibitors in novel preclinical models: LSCC organoids and patient-derived xenografts. Finally, we will assess if increased TNIK expression can serve as a biomarker to select patients that would benefit from treatment with TNIK inhibitors. Our studies will increase our knowledge on LSCC biology and aim to find a precise treatment for this disease. This project will enable Dr P Torres-Ayuso to develop a wide range of new and transferable skills, and will allow him to broaden his technical, mentoring, management and communication skills. He will benefit from the high calibre of the Cancer Research UK Manchester Institute, and the expertise of his supervisor (Dr J Brognard) who will aid in his development as a young scientist. This project will thus enable the Fellow to achieve his long-term objective of obtaining a leadership position in a competitive European Institute.

Location

Country

United Kingdom (UK)

Source

Source

EU Funding & Tenders Portal

URL

More Details

Record type

Project

Sector

Education

Article published date

2026-01-15

More on this project

Research

Free account

View all details

You are reading the public part. A free account opens the rest:

  • Every detail on this project
  • News and media coverage
  • Technical research
View all details

Free account · no card · lands you back on this project